Ironwood Pharmaceuticals Financials - Benzinga

Ironwood Pharmaceuticals Inc

IRWDNASDAQ

Trade with Public

Trade with Public

$3.50

-0.12-3.31%

Ult. Agg.: Oct 30, 6:48 PM

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Confronta Opzioni Rapporto azionario

© 2026 Benzinga | All Rights Reserved

Ironwood Pharmaceuticals Financials

Ironwood Pharmaceuticals (IRWD) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Ironwood Pharmaceuticals Raises FY2026 Sales Guidance from $450.000M-$475.000M to $460.000M-$485.000M vs $460.118M Est

Ironwood Pharmaceuticals (NASDAQ:IRWD) raises FY2026 sales outlook from $450.000 million-$475.000 million to $460.000 million-$485.000 million vs $460.118 million estimate.

Benzinga Newsdesk

PRO
Ironwood Pharmaceuticals Q2 Adj. EPS $0.31 Misses $0.36 Estimate, Sales $113.041M Miss $114.844M Estimate

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly earnings of $0.31 per share which missed the analyst consensus estimate of $0.36 by 13.89 percent. This is a 121.43 percent increase over earnings of $0.14 per

Benzinga Newsdesk

PRO
Ironwood Pharmaceuticals Affirms FY2026 Sales Guidance of $450.000M-$475.000M vs $458.593M Est

Ironwood Pharmaceuticals (NASDAQ:IRWD) affirms FY2026 sales outlook from $450.000 million-$475.000 million to $450.000 million-$475.000 million vs $458.593 million estimate.

Benzinga Newsdesk

PRO
Ironwood Pharmaceuticals Q1 Adj. EPS $0.24, Inline, Sales $106.506M Beat $92.088M Estimate

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly earnings of $0.24 per share which met the analyst consensus estimate. This is a 271.43 percent increase over losses of $(0.14) per share from the same period last

Benzinga Newsdesk

PRO
Ironwood Pharmaceuticals Affirms FY2026 Sales Guidance of $450.000M-$475.000M

Ironwood Pharmaceuticals (NASDAQ:IRWD) affirms FY2026 sales outlook from $450.000 million-$475.000 million to $450.000 million-$475.000 million.

Benzinga Newsdesk

PRO
Ironwood Pharmaceuticals Q4 Adj. EPS $(0.01) Misses $0.01 Estimate, Sales $47.709M Miss $50.933M Estimate

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $0.01 by 200 percent. This is a 200 percent decrease over earnings of $0.01 per share

Benzinga Newsdesk